Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Auditor change
|
Loxo Oncology, Inc. (LOXO)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/15/2019 |
8-K
| Quarterly results |
01/07/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 5, 2019 LOXO ONCOLOGY, INC. Delaware 001-36562 46-2996673 281 Tresser Blvd., 9th Floor Stamford, CT 06901 653-3880 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 und...",
"Agreement and Plan of Merger, by and among Eli Lilly and Company, Bowfin Acquisition Corporation and Loxo Oncology, Inc",
"Tender and Support Agreement, by and among Eli Lilly and Company, Bowfin Acquisition Corporation and Aisling Capital III, LP",
"Lilly Announces Agreement To Acquire Loxo Oncology" |
|
01/02/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
12/06/2018 |
8-K
| Regulation FD Disclosure |
11/27/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
11/08/2018 |
8-K
| Quarterly results |
09/17/2018 |
8-K
| Other Events |
08/09/2018 |
8-K
| Quarterly results |
06/14/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/04/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
05/08/2018 |
8-K
| Quarterly results |
03/01/2018 |
8-K
| Quarterly results |
02/21/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
01/08/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
12/27/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
12/04/2017 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
11/21/2017 |
8-K
| Entry into a Material Definitive Agreement |
11/14/2017 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
11/02/2017 |
8-K
| Quarterly results |
10/18/2017 |
8-K
| Quarterly results |
10/18/2017 |
8-K
| Quarterly results |
09/28/2017 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits
Docs:
|
"Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer STAMFORD, Conn., Sept 27, 2017 — Loxo Oncology, Inc. , a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced details of the LOXO-292 abstract that will be presented as a late-breaking oral presentation at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer being held from October 15-18, 2017, in Yokohama, Japan. LOXO-292 is Loxo Oncology's highly selective RET inhibitor. The abstract describes the first two patients with RET-fusion lung cancer with and without brain metastases treated with LOXO-292. Both patients ...",
"Abstract accepted for presentation at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer" |
|
08/08/2017 |
8-K
| Quarterly results |
07/31/2017 |
8-K
| Form 8-K - Current report: |
06/23/2017 |
8-K
| Form 8-K - Current report |
06/15/2017 |
8-K
| Form 8-K - Current report |
06/05/2017 |
8-K
| Form 8-K - Current report |
05/09/2017 |
8-K
| Form 8-K - Current report |
03/21/2017 |
8-K
| Form 8-K - Current report |
03/07/2017 |
8-K
| Form 8-K - Current report |
01/05/2017 |
8-K
| Form 8-K - Current report |
12/19/2016 |
8-K
| Form 8-K - Current report |
11/09/2016 |
8-K
| Form 8-K - Current report |
11/02/2016 |
8-K
| Form 8-K - Current report |
|
|
|